Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198865 | 0.84 | CTSS (0.48) | GSK3BPTPN1CTSSCTNNB1WNT3A | |
| SCHEMBL14797596 | 0.77 | GSK3B (0.43) | GSK3BPTPN1CES2HPGDSCES1 | |
| SCHEMBL7786308 | 0.77 | PTPN1 (0.47) | GSK3BPTPN1CES2CES1CTNNB1 | |
| SCHEMBL16914396 | 0.77 | PTPN1 (0.47) | GSK3BPTPN1CES2CES1CTNNB1 | |
| SCHEMBL1458482 | 0.77 | KDM4E (0.43) | CES2RXRARXRBCES1KAT6A | |
| SCHEMBL13389880 | 0.76 | ALDH1A1 (0.41) | CES2CTSSCES1LMNAGAA | |
| SCHEMBL5025538 | 0.76 | CES2 (0.40) | CES2CTSSCES1LMNAGAA | |
| SCHEMBL23358951 | 0.74 | HPGD (0.49) | GSK3BPTPN1CES2HPGDSCES1 | |
| SCHEMBL168979 | 0.74 | CTNNB1 (0.57) | GSK3BPTPN1CTNNB1WNT3ALMNA | |
| SCHEMBL30873662 | 0.74 | HPGD (0.49) | GSK3BPTPN1CES2HPGDSCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9073881-B2 | Benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041468-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | EIF4EBP1, EIF4E, EIF4A2 | GSK3B 2874/4885PTPN1 3778/4885CES2 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.